联检CEA-mRNA和CA19-9指标诊断与鉴别诊断恶性腹水的临床评价  

Detection of CEA-mRNA and CA19-9 in ascites for differential diagnosis of malignant ascites

作　　者：钟怀印[1] 张建华[1] 薛承岩[1] 

机构地区：[1]承德医学院附属医院,河北承德067000

出　　处：《中国实验诊断学》2006年第11期1337-1339,共3页Chinese Journal of Laboratory Diagnosis

摘　　要：目的分析CEA-mRNA和CA19-9指标在诊断与鉴别诊断恶性腹水方面的应用价值。方法采集腹水为检测标本,其中恶性腹水、良性腹水各32份。应用反转录-套式-聚合酶链反应(RT-NP-PCR)技术检测CEA-mRNA、磁分离酶联免疫测定技术(MAIA)方法检测CA19-9。结果良性腹水组,CEA-mRNA和CA19-9阳性率分别为6.2%(2/32)和0。恶性腹水组,CEA-mRNA和CA19-9阳性率分别为78.1%(25/32)和59.4%(19/32),特异性分别为93.8%和100%,两者联检的阳性率为87.5%(28/32)。恶性腹水组与良性腹水组检测结果的差别,均具有显著性(P<0.01)。结论在诊断和鉴别诊断恶性腹水方面,CEA-mRNA和CA19-9均具有较高的特异性和敏感性,具有较高的应用价值;两者联检,可以进一步提高检测敏感性。Objective To analyse the value of CEA-mRNA and CA19-9 that be detected in aseites for diagnosis and differential diagnosis of malignant or benign aseites. Methods There were 32 malignant aseites and 32 benign ascites in the study. CEA-mRNA was detected in ascites by reverse transcriptase-nested primers-polymerase chain reaction （RT-NP-PCR） and MAIA detected CA19-9 infi the specimens. Results In the benign ascites group, the positive rate of CEA-mRNA was 6.2% （2/32） and CA19-9 was 0. In the malignant ascites group, the positive rate of CEA-mRNA was 78.1% （25/32） and CA19-9 was 59.4% （19/32）, the specificity of CEA-mRNA was 93.8% and CA19-9 was 100%, the positive rate was 87.5% （28/32） when CEA-mRNA and CA19-9 was did combined detection. The difference positive results of CEA-mRNA and CA19-9 were significant between the malignant group and the benign group （P 〈 0.01）. Conclusion CEA-mRNA and CA19-9 are useful index in diagnosis and differential diagnosis of malignant ascites. Combined detection of them can improve the sensitivity.

关 键 词：CEA-MRNA CA19-9 恶性腹水 

分 类 号：R446.6[医药卫生—诊断学] R450[医药卫生—临床医学]